Peptides · Peptide comparison
Pramlintide vs Retatrutide
Synthetic amylin analog for comprehensive postprandial glucose control with insulin therapy
The world's first triple-action weight loss peptide that simultaneously activates three hormone receptors—GIP, GLP-1, and glucagon—delivering unprecedented weight loss results of up to 24% body weight in clinical trials [1][2].
- Weight Management
- Weight Management
At a glance
Quick comparison
Efficacy
Benefit ratings
Blood Sugar Control
Weight Management
Metabolic Health
Weight Loss Power
Appetite Control
Technical data
Compound specifications
Pramlintide
- Molecular formula
- C171H267N51O53S2
- Molecular weight
- 3,949 Da
- Half-life
- ~48 minutes
- Bioavailability
- 30-40% subcutaneous bioavailability
- CAS number
- 196078-30-5
Retatrutide
- Molecular formula
- C221H342N46O68
- Molecular weight
- 4731 g/mol
- Half-life
- ~6 days (allows once-weekly dosing)
- Bioavailability
- High via subcutaneous injection
- CAS number
- 2381089-83-2
Protocols
Dosing compared
Pramlintide
Subcutaneous
- Titrate up after 3+ days without significant nausea15 mcg per meal (type 1 diabetes)Immediately before each major meal · Titrate up after 3+ days without significant nauseaFDA Symlin label starting dose for type 1 diabetes. Inject before each major meal (>=250 kcal or >=30 g carbohydrate); reduce mealtime insulin by 50% when starting. [6]
- Ongoing, as tolerated30-60 mcg per meal (type 1 diabetes)Immediately before each major meal · Ongoing, as toleratedType 1 maintenance target per FDA label: titrate 15 -> 30 -> 45 -> 60 mcg, stepping up each time no significant nausea occurs for 3+ days; settle at 30 or 60 mcg as tolerated. [6]
- Increase to 120 mcg after 3+ days without significant nausea60 mcg per meal, titrating to 120 mcg (type 2 diabetes)Immediately before each major meal · Increase to 120 mcg after 3+ days without significant nauseaFDA Symlin label for type 2 diabetes: start 60 mcg, advance to 120 mcg maintenance as tolerated. Separate injection from insulin; cut mealtime insulin 50% at start. [6]
Retatrutide
Subcutaneous
- Weeks 1-42 mgOnce weekly · Weeks 1-4 (then escalate 2 mg every 4 weeks)Phase 2 obesity trial initiated higher-dose arms at 2 mg weekly with stepwise 2 mg increases every 4 weeks to limit GI effects [1].
- Maintenance after titration4-8 mgOnce weekly · Maintenance after titrationMid-range maintenance doses; 8 mg produced ~22% mean weight loss at 48 weeks in the phase 2 trial [1][3].
- Maintenance (highest studied)12 mgOnce weekly · Maintenance (highest studied)Highest studied dose; produced ~24% mean weight reduction at 48 weeks [1]. Still investigational (not FDA-approved).
Applications
Best suited for
Pramlintide
- Improving postprandial glucose control in insulin-treated diabetes
- Pramlintide is particularly well-suited for individuals focused on improving postprandial glucose control in insulin-treated diabetes. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [3][6].
- Reducing insulin dose requirements while maintaining glycemic control
- Pramlintide is particularly well-suited for individuals focused on reducing insulin dose requirements while maintaining glycemic control. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [3].
- Supporting weight management in insulin-treated T1DM and T2DM patients
- Pramlintide is particularly well-suited for individuals focused on supporting weight management in insulin-treated t1dm and t2dm patients. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [6].
- Addressing amylin deficiency in insulin-dependent diabetes
- Pramlintide is particularly well-suited for individuals focused on addressing amylin deficiency in insulin-dependent diabetes. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [1].
Retatrutide
- Significant Obesity Management
- If you need to lose a substantial amount of weight, retatrutide is showing unprecedented results. Phase 2 trials demonstrated average weight loss of 24% at the highest dose—that's nearly 60 pounds for someone weighing 250 lbs [1]. No other medication has matched this [1].
- Type 2 Diabetes with Obesity
- Retatrutide tackles both problems at once. It dramatically improves blood sugar control (HbA1c reductions of up to 2%) while delivering major weight loss [6]. The dual benefit makes it especially valuable for diabetics struggling with weight.
- Metabolic Syndrome Warriors
- If you're dealing with the cluster of issues that includes high blood sugar, excess belly fat, abnormal cholesterol, and high blood pressure, retatrutide's triple mechanism attacks multiple aspects of metabolic dysfunction simultaneously [5].
- Fatty Liver Disease (MASLD)
- Early research shows retatrutide may significantly reduce liver fat [7]. For people with non-alcoholic fatty liver disease, this peptide offers hope through weight loss plus direct metabolic improvements that benefit liver health.
Safety profile
Side effects
Pramlintide
Common
- Nausea
- Reduced Appetite / Anorexia
- Headache
Uncommon
- Abdominal Pain and Vomiting
- Injection Site Reactions
Serious
- Severe Hypoglycemia (BLACK BOX WARNING)
Retatrutide
Common
- Nausea
- Diarrhea
- Constipation
- Decreased appetite
Uncommon
- Increased heart rate
- Injection site reactions
Serious
- Pancreatitis
- Gallbladder problems
Research status
Safety & evidence
Pramlintide
- Evidence level
- Strong human trials (Phase 3 or FDA approved)
- FDA status
- FDA approved for this use
- Safety overview
- FDA-approved pramlintide demonstrates good tolerability in insulin-treated diabetes with well-characterized safety profile from >20 years clinical use. Gastrointestinal side effects (nausea) occur in 30-50% of initiators but typically resolve within 1-3 weeks. Hypoglycemia risk, especially when combined with insulin, requires dose coordination and patient education. [6] Pancreatic side effects theoretically possible but not documented in clinical trials. Pregnancy category C requires careful consideration.
Contraindications
- Confirmed gastroparesis [6] requiring treatment
- Hypoglycemia unawareness (inability to recognize hypoglycemic symptoms) [6]
- Known hypersensitivity to pramlintide or metacresol [6]
- Pediatric patients (safety not established in children) [6]
Retatrutide
- Evidence level
- Moderate human trials (Phase 1-2)
- FDA status
- Research compound
- Safety overview
- Retatrutide has shown a generally favorable safety profile in Phase 1 and Phase 2 clinical trials involving over 600 participants [1][6]. Most side effects are gastrointestinal and tend to improve over time [3]. The medication appears well-tolerated when doses are increased gradually. No major safety signals have emerged, but larger Phase 3 trials are still ongoing [3].
Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Pregnancy or planning to become pregnant
- History of severe pancreatitis
- Known allergy to GLP-1 receptor agonists
Decision guide
Which is right for you?
Pramlintide
Choose Pramlintide if…
- Improving postprandial glucose control in insulin-treated diabetes
- Reducing insulin dose requirements while maintaining glycemic control
- Supporting weight management in insulin-treated T1DM and T2DM patients
- Addressing amylin deficiency in insulin-dependent diabetes
Retatrutide
Choose Retatrutide if…
- Significant weight loss
- Type 2 diabetes management
- Metabolic health improvement
- Body composition optimization